Clinical TrialsPositive top-line data emerged from the Phase 3 trial evaluating giroctogene fitelparvovec, a one-time gene therapy being developed in collaboration with Pfizer in hemophilia A.
FinancialsThe Genentech partnership further validates Sangamo's differentiated gene editing and CNS-delivery capabilities.
PartnershipsCollaboration discussions are progressing with three biotechnology companies, which may further validate Sangamo's differentiated gene editing capabilities.